KLK3 and prostate carcinoma: The researchers constructed a CRISPR-dCas9-KRAB system driven by the PSA promoter that inhibits PSA gene expression in prostate cancer cells at the transcriptional level, thereby suppressing malignant growth and migration of cancer cells and promoting their apoptosis.